köpa viagra billigt nebenwirkungen cialis generika
  • http://gev.industrie.gouv.fr/CACHE/well/... acheter viagra cialis levitra pas cher
  • acheter viagra et cialis en ligne cialis pharmacie europenne
    achat viagra en ligne pas cher viagra ne marche pas viagra rezeptfrei per nachnahme kamagra versand propecia pharmacie viagra netistä ordina levitra viagra reseptfritt
    viagra pilule tadalafil sans ordonnance acheter levitra a andorre
  • viagra bas prix http://humanidades.uprrp.edu/index.php?s... acquisto cialis in italia
  • Tag Archive | "Radiation Therapy Oncology Group"

    Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer

    Monday, June 11, 2012

    0 Comments

    Source: Journal of Clinical Oncology Purpose Tobacco smoking is associated with oropharynx cancer survival, but to what extent cancer progression or death increases with increasing tobacco exposure is unknown. Patients and Methods Patients with oropharynx cancer enrolled onto a phase III trial of radiotherapy from 1991 to 1997 (Radiation Therapy Oncology Group [RTOG] 9003) or […]

    Continue reading...

    Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer

    Tuesday, May 8, 2012

    0 Comments

    Source: Journal of Clinical Oncology Abstract Purpose Tobacco smoking is associated with oropharynx cancer survival, but to what extent cancer progression or death increases with increasing tobacco exposure is unknown. Patients and methods Patients with oropharynx cancer enrolled onto a phase III trial of radiotherapy from 1991 to 1997 (Radiation Therapy Oncology Group [RTOG] 9003) […]

    Continue reading...

    Prognostic Significance of HPV Status in Oropharyngeal Cancer

    Wednesday, April 18, 2012

    0 Comments

    OncologySTAT Editorial Team Dr. Maura Gillison is Professor of Medicine, Epidemiology, and Otolaryngology at Ohio State University in Columbus. OncologySTAT: The results of the Radiation Therapy Oncology Group (RTOG) 0129 trial showed that the human papillomavirus (HPV) is an independent prognostic factor in oropharyngeal cancer. Could you tell us about the rationale for this study? […]

    Continue reading...

    Cisplatin Aids Survival of High-Risk Head and Neck Cancer

    Wednesday, February 8, 2012

    0 Comments

    Source: Oncology Report Adding chemotherapy to radiotherapy improved 10-year survival of resectable head and neck carcinomas among high-risk patients who had microscopically involved resection margins and/or extracapsular spread of disease – but not in high-risk patients who only had tumor in multiple lymph nodes. The findings come from a long-term update and unplanned subset analysis […]

    Continue reading...

    New Therapies and Prognostic Techniques Highlighted in Head and Neck Cancer

    Tuesday, October 18, 2011

    0 Comments

    The Asco Post D. Neil Hayes, MD, MPH, of the University of North Carolina at Chapel Hill, described efforts to position the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) in head and neck cancer treatment. Surprisingly negative results came from the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940), which showed […]

    Continue reading...

    ASCO: HPV Infection Linked to Better Outcome in Oropharyngeal Cancer

    Friday, May 15, 2009

    0 Comments

    Source: MedpageToday.com  Author: Michael Smith TORONTO, May 14 — Patients with oropharyngeal cancer had a 50% lower five-year mortality risk when they also had human papillomavirus (HPV) infection, according to data from a randomized clinical trial. HPV-positive patients had a two-year overall survival of 88% compared with 66% for HPV-negative patients (P<0.001), said Maura Gillison, […]

    Continue reading...